Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis

Takao Koike, Masayoshi Harigai, Shigeko Inokuma, Naoki Ishiguro, Junnosuke Ryu, Tsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka, Koichi Fujii, Takunari Yoshinaga, Bruce Freundlich, Michio Suzukawa

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Our aim was to evaluate real-world safety and effectiveness in a 6-month postmarketing surveillance study covering all Japanese patients with rheumatoid arthritis (RA) who received etanercept during a 2-year period. Data for 13,894 patients (1334 sites) enrolled between March 2005 and April 2007 were collected. Adverse events (AEs) and serious adverse events (SAEs) were reported in 4336 (31.2%) and 857 (6.2%) patients, respectively. The most frequent AEs were injection site reactions (n = 610, 4.4%) and rash (n = 339, 2.4%), whereas pneumonia (n = 116, 0.8%) and interstitial lung disease (n = 77, 0.6%) were the most frequent SAEs. Significant improvement in the proportion of patients with a good European League Against Rheumatism (EULAR) response was observed from week 4 (17.6%) to week 24 (31.6%) (p<0.001); 84.3% of patients had good or moderate EULAR responses at week 24. The percentage of patients achieving remission increased significantly from week 4 (9.3%) to week 24 (18.9%) (p<0.001). Patients with early moderate RA were less likely to experience SAEs and were more likely to achieve remission compared with patients with more severe disease. The safety and effectiveness of etanercept was demonstrated in Japanese patients in one of the largest observational trials conducted thus far in RA patients treated with biologics.

Original languageEnglish
Pages (from-to)343-351
Number of pages9
JournalModern Rheumatology
Volume21
Issue number4
DOIs
Publication statusPublished - 2011 Aug

Fingerprint

Rheumatoid Arthritis
Safety
Etanercept
Interstitial Lung Diseases
Exanthema
Rheumatic Diseases
Biological Products
Pneumonia
Injections

Keywords

  • DAS28
  • Etanercept
  • Postmarketing surveillance study
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. / Koike, Takao; Harigai, Masayoshi; Inokuma, Shigeko; Ishiguro, Naoki; Ryu, Junnosuke; Takeuchi, Tsutomu; Tanaka, Yoshiya; Yamanaka, Hisashi; Fujii, Koichi; Yoshinaga, Takunari; Freundlich, Bruce; Suzukawa, Michio.

In: Modern Rheumatology, Vol. 21, No. 4, 08.2011, p. 343-351.

Research output: Contribution to journalArticle

Koike, T, Harigai, M, Inokuma, S, Ishiguro, N, Ryu, J, Takeuchi, T, Tanaka, Y, Yamanaka, H, Fujii, K, Yoshinaga, T, Freundlich, B & Suzukawa, M 2011, 'Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis', Modern Rheumatology, vol. 21, no. 4, pp. 343-351. https://doi.org/10.1007/s10165-010-0406-3
Koike, Takao ; Harigai, Masayoshi ; Inokuma, Shigeko ; Ishiguro, Naoki ; Ryu, Junnosuke ; Takeuchi, Tsutomu ; Tanaka, Yoshiya ; Yamanaka, Hisashi ; Fujii, Koichi ; Yoshinaga, Takunari ; Freundlich, Bruce ; Suzukawa, Michio. / Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. In: Modern Rheumatology. 2011 ; Vol. 21, No. 4. pp. 343-351.
@article{12d42b403d7b45be85c07f7ea9ba5dc4,
title = "Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis",
abstract = "Our aim was to evaluate real-world safety and effectiveness in a 6-month postmarketing surveillance study covering all Japanese patients with rheumatoid arthritis (RA) who received etanercept during a 2-year period. Data for 13,894 patients (1334 sites) enrolled between March 2005 and April 2007 were collected. Adverse events (AEs) and serious adverse events (SAEs) were reported in 4336 (31.2{\%}) and 857 (6.2{\%}) patients, respectively. The most frequent AEs were injection site reactions (n = 610, 4.4{\%}) and rash (n = 339, 2.4{\%}), whereas pneumonia (n = 116, 0.8{\%}) and interstitial lung disease (n = 77, 0.6{\%}) were the most frequent SAEs. Significant improvement in the proportion of patients with a good European League Against Rheumatism (EULAR) response was observed from week 4 (17.6{\%}) to week 24 (31.6{\%}) (p<0.001); 84.3{\%} of patients had good or moderate EULAR responses at week 24. The percentage of patients achieving remission increased significantly from week 4 (9.3{\%}) to week 24 (18.9{\%}) (p<0.001). Patients with early moderate RA were less likely to experience SAEs and were more likely to achieve remission compared with patients with more severe disease. The safety and effectiveness of etanercept was demonstrated in Japanese patients in one of the largest observational trials conducted thus far in RA patients treated with biologics.",
keywords = "DAS28, Etanercept, Postmarketing surveillance study, Rheumatoid arthritis",
author = "Takao Koike and Masayoshi Harigai and Shigeko Inokuma and Naoki Ishiguro and Junnosuke Ryu and Tsutomu Takeuchi and Yoshiya Tanaka and Hisashi Yamanaka and Koichi Fujii and Takunari Yoshinaga and Bruce Freundlich and Michio Suzukawa",
year = "2011",
month = "8",
doi = "10.1007/s10165-010-0406-3",
language = "English",
volume = "21",
pages = "343--351",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis

AU - Koike, Takao

AU - Harigai, Masayoshi

AU - Inokuma, Shigeko

AU - Ishiguro, Naoki

AU - Ryu, Junnosuke

AU - Takeuchi, Tsutomu

AU - Tanaka, Yoshiya

AU - Yamanaka, Hisashi

AU - Fujii, Koichi

AU - Yoshinaga, Takunari

AU - Freundlich, Bruce

AU - Suzukawa, Michio

PY - 2011/8

Y1 - 2011/8

N2 - Our aim was to evaluate real-world safety and effectiveness in a 6-month postmarketing surveillance study covering all Japanese patients with rheumatoid arthritis (RA) who received etanercept during a 2-year period. Data for 13,894 patients (1334 sites) enrolled between March 2005 and April 2007 were collected. Adverse events (AEs) and serious adverse events (SAEs) were reported in 4336 (31.2%) and 857 (6.2%) patients, respectively. The most frequent AEs were injection site reactions (n = 610, 4.4%) and rash (n = 339, 2.4%), whereas pneumonia (n = 116, 0.8%) and interstitial lung disease (n = 77, 0.6%) were the most frequent SAEs. Significant improvement in the proportion of patients with a good European League Against Rheumatism (EULAR) response was observed from week 4 (17.6%) to week 24 (31.6%) (p<0.001); 84.3% of patients had good or moderate EULAR responses at week 24. The percentage of patients achieving remission increased significantly from week 4 (9.3%) to week 24 (18.9%) (p<0.001). Patients with early moderate RA were less likely to experience SAEs and were more likely to achieve remission compared with patients with more severe disease. The safety and effectiveness of etanercept was demonstrated in Japanese patients in one of the largest observational trials conducted thus far in RA patients treated with biologics.

AB - Our aim was to evaluate real-world safety and effectiveness in a 6-month postmarketing surveillance study covering all Japanese patients with rheumatoid arthritis (RA) who received etanercept during a 2-year period. Data for 13,894 patients (1334 sites) enrolled between March 2005 and April 2007 were collected. Adverse events (AEs) and serious adverse events (SAEs) were reported in 4336 (31.2%) and 857 (6.2%) patients, respectively. The most frequent AEs were injection site reactions (n = 610, 4.4%) and rash (n = 339, 2.4%), whereas pneumonia (n = 116, 0.8%) and interstitial lung disease (n = 77, 0.6%) were the most frequent SAEs. Significant improvement in the proportion of patients with a good European League Against Rheumatism (EULAR) response was observed from week 4 (17.6%) to week 24 (31.6%) (p<0.001); 84.3% of patients had good or moderate EULAR responses at week 24. The percentage of patients achieving remission increased significantly from week 4 (9.3%) to week 24 (18.9%) (p<0.001). Patients with early moderate RA were less likely to experience SAEs and were more likely to achieve remission compared with patients with more severe disease. The safety and effectiveness of etanercept was demonstrated in Japanese patients in one of the largest observational trials conducted thus far in RA patients treated with biologics.

KW - DAS28

KW - Etanercept

KW - Postmarketing surveillance study

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=83255188765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83255188765&partnerID=8YFLogxK

U2 - 10.1007/s10165-010-0406-3

DO - 10.1007/s10165-010-0406-3

M3 - Article

VL - 21

SP - 343

EP - 351

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 4

ER -